Streetbeat News

Stock Prices

RILY

B. Riley Financial, Inc. (NASDAQ:RILY) stock has declined over 37% in the last five days due to continued downward momentum. The company became the largest minority shareholder in Franchise Group (FRG) after leading its equity financing in August. FRG's credit rating was downgraded by S&P, and its CEO is under investigation in a federal fraud case. B. Riley reported Q3 losses of $2.53 per share, a significant decrease from the previous year, despite a 48% increase in quarterly sales. The stock's trading volume surged, with over 3.67 million shares traded compared to the 100-day average of 375 thousand shares.

Portfolio Pulse from Erica Kollmann

November 13, 2023 | 7:14 pm

USO

U.S. total shale regions oil production for December is projected to decrease by approximately 1,200 barrels per day (BPD), reaching 9.652 million BPD. This represents a smaller decline compared to the 4,100 BPD fall in November, as reported by Reuters.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 7:11 pm

AMD

ARM

INTC

Citi analyst Christopher Danely has reiterated a Buy rating on Advanced Micro Devices, Inc (AMD), noting that the company has gained significant market share in MPU units according to Mercury Research's estimates for 3Q23. AMD's market share increased to 17.7%, while Intel Corp (INTC) and Arm Holdings Plc (ARM) saw declines in their shares. Danely projects higher EPS for AMD in CY23 and CY24 compared to consensus estimates. AMD's stock traded lower by 1.62% at the last check.

Portfolio Pulse from Anusuya Lahiri

November 13, 2023 | 7:04 pm

LLY

NVO

PFE

Pfizer Inc (PFE) is targeting the obesity pill market with its experimental drug, danuglipron, aiming for a $10 billion segment. Pfizer discontinued another candidate, lotiglipron, due to unsatisfactory Phase 1 results. Competitors Eli Lilly (LLY) and Novo Nordisk (NVO) have set high standards in the weight loss drug industry. Pfizer's upcoming phase two trial data for danuglipron is eagerly awaited by investors, with results expected by year-end for the twice-daily pill and early next year for a once-daily version. Despite a 40% share price drop, Pfizer's CEO sees a $90 billion market potential for GLP-1s. Analysts highlight the need for Pfizer's pill to achieve a 14%-15% weight loss to compete with Eli Lilly's product. PFE shares were down 1.44% at $29.06 on the last check Monday.

Portfolio Pulse from Vandana Singh

November 13, 2023 | 7:04 pm

RHP

Ryman Hospitality Props (NYSE:RHP) has received 4 analyst ratings in the last quarter, with 1 bullish and 3 somewhat bullish. The average 12-month price target among these analysts is $105.0, with a high of $123.00 and a low of $94.00. This target has decreased by 5.83% from the previous average of $111.50. Analyst ratings are periodic evaluations from financial experts based on company performance and projections.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 7:00 pm

FILUSD

Filecoin (CRYPTO: FIL) has seen a significant increase of 9.56% in its price over the past 24 hours, reaching $5.3. Over the last week, FIL has gained 22.0%, rising from $4.35. The coin's all-time high is $236.84. Trading volume has surged by 255.0% in the past week, and the circulating supply has grown by 1.13% to over 469.02 million, which is 23.92% of the max supply. Filecoin's market cap is currently ranked #31, valued at $2.49 billion.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 7:00 pm

DOTUSD

Polkadot's (CRYPTO: DOT) price has decreased by 3.62% in the last 24 hours to $5.5, contrasting with a 12.0% increase over the past week. The trading volume has risen by 43.0%, and the circulating supply has grown by 0.31% to 1.30 billion. Polkadot's market cap is currently ranked #14 at $7.13 billion.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 7:00 pm

AVAX-USD

Avalanche (CRYPTO: AVAX) has seen a price drop of 5.97% in the past 24 hours, now at $17.09, despite a 32.0% gain over the past week. The trading volume has increased by 263.0%, while the circulating supply decreased by 0.12%. The current market cap is $6.09 billion, ranking AVAX at #15.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 7:00 pm

CTAS

Truist Securities analyst Jasper Bibb initiated coverage on Cintas Corp (NASDAQ:CTAS) with a Buy rating and a price target of $625. Bibb expects Cintas to achieve high incremental margins and a 10%+ increase in FY26 consensus EPS over the next 24 months due to moderating wage inflation, favorable material pricing trends, and Smart Truck initiative efficiencies. The First Aid and Fire segments are projected to deliver a ~10% organic CAGR over five years, improving segment margins to over 20%. Share repurchases are anticipated to increase in FY24/FY25 with net leverage at 1.0x. Bibb's EPS estimates for FY25 and FY24 are $16.92 and $14.22, respectively, both above consensus.

Portfolio Pulse from Lekha Gupta

November 13, 2023 | 6:58 pm

AAPL

Citi analyst Atif Malik observed that Apple Inc's Taiwanese suppliers, including Hon Hai, Pegatron, and Wistron, reported a 10% month-on-month sales growth for October, outperforming the 3-year average seasonality. Despite concerns about iPhone sell-through in China with the Huawei Mate 60 launch, U.S. sales remain strong. Malik has not observed supply chain build cuts and maintains his estimate of 81 million iPhone 15 units for CY23. Apple's stock traded down by 0.76% at $184.98.

Portfolio Pulse from Anusuya Lahiri

November 13, 2023 | 6:51 pm